Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-09 · accession 0002009236-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-11 | 2026-02-09 | REGN | Pitofsky Jason | SVP Ctrl | S - Sale+OE | $778.52 | -2,036 | 5,376 | -27% | -$1.59M |
| D | 2026-02-11 | 2026-02-09 | REGN | Pitofsky Jason | SVP Ctrl | M - OptEx | $492.00 | +1,000 | 6,308 | +19% | +$492.0K |
| D | 2026-02-11 | 2026-02-09 | REGN | Pitofsky Jason | SVP Ctrl | M - OptEx | $0.00 | -1,000 | 905 | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | S | D | 521 | $776.43 | 5,767 | D | — | — | (F2) Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 2 | Common | Common Stock | 2026-02-09 | S | D | 53 | $785.72 | 4,272 | D | — | — | (F10) Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 3 | Common | Common Stock | 2026-02-09 | S | D | 1 | $784.66 | 4,325 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-09 | S | D | 144 | $783.23 | 4,326 | D | — | — | (F9) Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 5 | Common | Common Stock | 2026-02-09 | S | D | 37 | $782.67 | 4,470 | D | — | — | (F8) Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 6 | Common | Common Stock | 2026-02-09 | S | D | 26 | $781.37 | 4,507 | D | — | — | (F7) Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 7 | Common | Common Stock | 2026-02-09 | S | D | 75 | $780.06 | 4,533 | D | — | — | (F6) Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 8 | Common | Common Stock | 2026-02-09 | S | D | 205 | $779.56 | 4,608 | D | — | — | (F5) Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 9 | Common | Common Stock | 2026-02-09 | S | D | 563 | $778.35 | 4,813 | D | — | — | (F4) Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 10 | Common | Common Stock | 2026-02-09 | M | A | 1,000 | $492.00 | 6,308 | D | — | — | |
| 11 | Common | Common Stock | 2026-02-09 | S | D | 20 | $775.95 | 6,288 | D | — | — | |
| 12 | Common | Common Stock | 2026-02-09 | S | D | 391 | $777.51 | 5,376 | D | — | — | (F3) Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| 13 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-02-09 | M | D | 1,000 | $0.00 | 905 | D | $492.00 · — to 2030-12-09 | 1,000 Common Stock | (F11) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |